Literature DB >> 26828056

End TB with precision treatment!

Evelien P M van der Burgt1, Marieke G G Sturkenboom1, Mathieu S Bolhuis1, Onno W Akkerman2, Jos G W Kosterink1, Wiel C M de Lange2, Frank G J Cobelens3, Tjip S van der Werf4, Jan-Willem C Alffenaar5.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26828056     DOI： 10.1183/13993003.01285-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  13 in total

1.  Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Authors:  Jan-Willem C Alffenaar; Simon Tiberi; Roger K Verbeeck; Scott K Heysell; Martin P Grobusch
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

2.  Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Samiksha Ghimire; Bhagwan Maharjan; Erwin M Jongedijk; Jos G W Kosterink; Gokarna R Ghimire; Daan J Touw; Tjip S van der Werf; Bhabana Shrestha; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.

Authors:  Reihaneh Abolhassani-Chimeh; Onno W Akkerman; Antonia M I Saktiawati; Nieko C Punt; Mathieu S Bolhuis; Yanri W Subronto; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar; Marieke G G Sturkenboom
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

4.  Clinical standards for drug-susceptible pulmonary TB.

Authors:  O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-07-01       Impact factor: 3.427

5.  Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay.

Authors:  Katarina Niward; Linnea Ek Blom; Lina Davies Forsman; Judith Bruchfeld; Erik Eliasson; Thomas Schön; Erja Chryssanthou; Jakob Paues
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.

Authors:  Daan J Touw; Giovanni B Migliori; Jan-Willem Alffenaar; Simone Hj van den Elsen; Marieke Gg Sturkenboom; Onno Akkerman; Linda Barkane; Judith Bruchfeld; Geoffrey Eather; Scott K Heysell; Henadz Hurevich; Liga Kuksa; Heinke Kunst; Johanna Kuhlin; Katerina Manika; Charalampos Moschos; Stellah G Mpagama; Marcela Muñoz Torrico; Alena Skrahina; Giovanni Sotgiu; Marina Tadolini; Simon Tiberi; Francesca Volpato; Tjip S van der Werf; Malcolm R Wilson; Joaquin Zúñiga
Journal:  BMJ Open       Date:  2020-06-16       Impact factor: 2.692

7.  High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Authors:  Charlotte Seijger; Wouter Hoefsloot; Inge Bergsma-de Guchteneire; Lindsey Te Brake; Jakko van Ingen; Saskia Kuipers; Reinout van Crevel; Rob Aarnoutse; Martin Boeree; Cecile Magis-Escurra
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

8.  Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.

Authors:  Jan-Willem C Alffenaar; Tawanda Gumbo; Kelly E Dooley; Charles A Peloquin; Helen Mcilleron; Andre Zagorski; Daniela M Cirillo; Scott K Heysell; Denise Rossato Silva; Giovanni Battista Migliori
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

9.  Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study.

Authors:  Samiksha Ghimire; Samriddhi Karki; Bhagwan Maharjan; Jos G W Kosterink; Daan J Touw; Tjip S van der Werf; Bhabana Shrestha; Jan-Willem Alffenaar
Journal:  BMJ Open Respir Res       Date:  2020-08

10.  A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva.

Authors:  Jan-Willem C Alffenaar; Erwin M Jongedijk; Claudia A J van Winkel; Margaretha Sariko; Scott K Heysell; Stellah Mpagama; Daan J Touw
Journal:  J Antimicrob Chemother       Date:  2021-01-19       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.